Enalaprilat (dihydrate)

Enalaprilat dihydrate (MK-422), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat dihydrate can be used for the research of hypertension[1][2][3].

Product Specifications

CAS Number

[84680-54-6]

Product Name Alternative

MK-422

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin-converting Enzyme (ACE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Enalaprilat-dihydrate.html

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 12.5 mg/mL (ultrasonic)

Smiles

O=C(O)[C@H]1N(C([C@H](C)N[C@H](C(O)=O)CCC2=CC=CC=C2)=O)CCC1.O.O

Molecular Formula

C18H28N2O7

Molecular Weight

384.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Ceconi C, et, al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22;577 (1-3) :1-6.|[2]Eickels M, et, al. Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol. 2000 Dec;131 (8) :1592-6. |[3]Loftsson T, et, al. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Acta Ophthalmol. 2010 May;88 (3) :337-41.